China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

 
• By Dexter Jie Yan
define
China's public payer is attempting to define innovation in drug development while capping innovative drug prices. • Source: Shutterstock

More from China

More from Asia